Share Price and Basic Stock Data
Last Updated: January 9, 2026, 3:57 am
| PEG Ratio | 2.58 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Shilpa Medicare Ltd operates within the pharmaceuticals sector, focusing on the development and manufacturing of generic drugs, particularly in oncology. As of the latest reporting, the company’s stock price stood at ₹318, with a market capitalization of ₹6,222 Cr. Over the past fiscal year, Shilpa Medicare reported sales of ₹1,046 Cr for FY 2023, which marked a decline from ₹1,141 Cr in FY 2022. However, the trailing twelve months (TTM) sales rose to ₹1,342 Cr, indicating a rebound in revenue generation. Quarterly sales figures reveal a positive trend, with ₹313 Cr reported in Sep 2023, up from ₹260 Cr in Jun 2023. The company’s operational efficiency is reflected in its operating profit margin (OPM), which improved from 9% in FY 2023 to 27% in the TTM period. This increase in OPM showcases better cost management and operational effectiveness, a crucial aspect for sustaining growth amidst competitive pressures in the pharmaceutical industry.
Profitability and Efficiency Metrics
Shilpa Medicare’s profitability metrics reveal a mixed performance. The reported net profit for FY 2023 was ₹-31 Cr, a sharp decline compared to ₹61 Cr in FY 2022. However, net profit increased significantly in the TTM to ₹137 Cr, reflecting a strong recovery. The company’s earnings per share (EPS) for FY 2025 is reported at ₹4.00, recovering from a loss of ₹-3.74 in FY 2023. Notably, the interest coverage ratio stood at 4.50x, indicating the company’s ability to cover interest expenses comfortably, which is favorable compared to the industry average. The return on equity (ROE) was reported at 4.21%, while the return on capital employed (ROCE) improved to 8.61%, suggesting enhanced capital efficiency. The cash conversion cycle (CCC) stood at 350 days, which is relatively high and may indicate liquidity challenges, although Shilpa Medicare’s operational improvements could mitigate this issue over time.
Balance Sheet Strength and Financial Ratios
Shilpa Medicare’s balance sheet reflects a robust financial structure, with total assets amounting to ₹3,495 Cr as of Sep 2025. The company’s reserves have grown substantially, reaching ₹2,427 Cr, while borrowings stood at ₹593 Cr, representing a manageable debt-to-equity ratio of 0.24. This low leverage suggests a conservative approach to financing, which may appeal to investors seeking stability. Moreover, the book value per share increased to ₹242.58, indicating strengthening shareholder equity. The current ratio is reported at 1.46, which indicates good short-term financial health, while the quick ratio of 0.94 suggests potential liquidity concerns in fulfilling immediate obligations. The price-to-book value ratio of 2.73x, while higher than the sector average, reflects market confidence in the company’s future growth prospects, albeit at a premium valuation compared to its book value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Shilpa Medicare indicates a stable ownership structure, with promoters holding 44.23% of the equity. Foreign institutional investors (FIIs) accounted for 10.92%, while domestic institutional investors (DIIs) held 7.67%. The public ownership stood at 37.18%, with a total of 52,065 shareholders. The gradual decline in promoter holdings from 50.01% in Dec 2022 to the current level may raise some concerns about insider confidence. However, the increase in FII participation from 8.60% in Sep 2023 to 10.92% in Sep 2025 reflects growing investor interest and confidence in the company’s recovery trajectory. Additionally, the shareholder base has expanded, indicating a broader acceptance of the stock among retail investors, which is a positive sign for future capital raising and market liquidity.
Outlook, Risks, and Final Insight
Shilpa Medicare’s outlook appears cautiously optimistic, driven by recent improvements in operational efficiency and a rebound in net profit. However, risks remain, particularly regarding the high cash conversion cycle, which could strain liquidity. Additionally, the pharmaceutical industry is fraught with regulatory challenges and pricing pressures that could impact future profitability. The company’s ability to maintain its growth trajectory will depend on its strategic initiatives, including expanding its product portfolio and enhancing market penetration. If the company can successfully navigate these challenges while leveraging its operational improvements, it may see continued growth. Conversely, failure to manage costs effectively or adapt to market changes could hinder its performance. The overall sentiment remains positive, with a focus on sustained operational improvements and strategic growth initiatives.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,404 Cr. | 404 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.25 Cr | 1,144.26 | 53.56 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 263 | 262 | 264 | 260 | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 |
| Expenses | 253 | 231 | 227 | 214 | 255 | 222 | 222 | 222 | 258 | 239 | 254 | 231 | 262 |
| Operating Profit | 10 | 31 | 37 | 46 | 58 | 65 | 70 | 70 | 86 | 81 | 77 | 91 | 108 |
| OPM % | 4% | 12% | 14% | 18% | 19% | 23% | 24% | 24% | 25% | 25% | 23% | 28% | 29% |
| Other Income | 4 | 3 | 2 | 2 | 2 | 2 | 9 | 10 | 5 | 1 | -18 | 6 | 2 |
| Interest | 13 | 18 | 18 | 18 | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 |
| Depreciation | 23 | 24 | 26 | 27 | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 |
| Profit before tax | -22 | -8 | -4 | 3 | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 |
| Tax % | -17% | -13% | 90% | 64% | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% |
| Net Profit | -19 | -7 | -8 | 1 | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 |
| EPS in Rs | -1.07 | -0.38 | -0.46 | 0.07 | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.40 | 2.25 |
Last Updated: December 29, 2025, 4:26 am
Below is a detailed analysis of the quarterly data for Shilpa Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 370.00 Cr.. The value appears strong and on an upward trend. It has increased from 321.00 Cr. (Jun 2025) to 370.00 Cr., marking an increase of 49.00 Cr..
- For Expenses, as of Sep 2025, the value is 262.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 231.00 Cr. (Jun 2025) to 262.00 Cr., marking an increase of 31.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 108.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 17.00 Cr..
- For OPM %, as of Sep 2025, the value is 29.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Jun 2025) to 29.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Sep 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 19.00 Cr. (Jun 2025) to 16.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Jun 2025) to 30.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Jun 2025) to 64.00 Cr., marking an increase of 14.00 Cr..
- For Tax %, as of Sep 2025, the value is 32.00%. The value appears to be increasing, which may not be favorable. It has increased from 5.00% (Jun 2025) to 32.00%, marking an increase of 27.00%.
- For Net Profit, as of Sep 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Jun 2025) to 44.00 Cr., marking a decrease of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.25. The value appears to be declining and may need further review. It has decreased from 2.40 (Jun 2025) to 2.25, marking a decrease of 0.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:39 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 571 | 614 | 719 | 779 | 789 | 733 | 908 | 899 | 1,141 | 1,046 | 1,146 | 1,281 | 1,342 |
| Expenses | 455 | 485 | 566 | 614 | 634 | 585 | 688 | 718 | 940 | 947 | 907 | 965 | 985 |
| Operating Profit | 116 | 129 | 153 | 165 | 155 | 148 | 219 | 181 | 202 | 99 | 239 | 316 | 356 |
| OPM % | 20% | 21% | 21% | 21% | 20% | 20% | 24% | 20% | 18% | 9% | 21% | 25% | 27% |
| Other Income | 6 | 5 | 5 | 15 | 22 | 33 | 17 | 90 | 21 | 17 | 15 | -5 | -9 |
| Interest | 4 | 4 | 7 | 3 | 3 | 4 | 5 | 22 | 41 | 59 | 92 | 76 | 61 |
| Depreciation | 23 | 21 | 29 | 31 | 37 | 42 | 44 | 54 | 80 | 96 | 108 | 113 | 116 |
| Profit before tax | 95 | 108 | 122 | 146 | 137 | 136 | 188 | 195 | 102 | -38 | 54 | 122 | 171 |
| Tax % | 21% | 33% | 19% | 29% | 25% | 19% | 18% | 25% | 41% | -19% | 41% | 36% | |
| Net Profit | 75 | 73 | 99 | 104 | 103 | 110 | 155 | 146 | 61 | -31 | 32 | 78 | 137 |
| EPS in Rs | 5.14 | 4.78 | 6.73 | 6.71 | 6.45 | 6.88 | 9.57 | 9.06 | 3.49 | -1.87 | 1.84 | 4.00 | 7.01 |
| Dividend Payout % | 5% | 6% | 4% | 4% | 5% | 7% | 6% | 6% | 16% | 0% | 0% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2.67% | 35.62% | 5.05% | -0.96% | 6.80% | 40.91% | -5.81% | -58.22% | -150.82% | 203.23% | 143.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 38.28% | -30.57% | -6.01% | 7.76% | 34.11% | -46.72% | -52.41% | -92.60% | 354.05% | -59.48% |
Shilpa Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 4% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -11% |
| 3 Years: | 16% |
| TTM: | 213% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 11% |
| 3 Years: | 29% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 |
| Reserves | 389 | 539 | 639 | 979 | 1,077 | 1,189 | 1,321 | 1,471 | 1,814 | 1,775 | 1,800 | 2,362 | 2,427 |
| Borrowings | 118 | 189 | 221 | 241 | 191 | 194 | 390 | 846 | 683 | 798 | 937 | 588 | 593 |
| Other Liabilities | 163 | 169 | 194 | 244 | 223 | 218 | 270 | 308 | 370 | 323 | 347 | 351 | 465 |
| Total Liabilities | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 | 3,495 |
| Fixed Assets | 294 | 316 | 580 | 492 | 534 | 558 | 650 | 1,111 | 1,342 | 1,368 | 1,385 | 1,418 | 1,801 |
| CWIP | 111 | 222 | 95 | 141 | 210 | 429 | 666 | 541 | 506 | 655 | 719 | 822 | 534 |
| Investments | 10 | 66 | 53 | 253 | 140 | 2 | 10 | 21 | 34 | 43 | 40 | 35 | 32 |
| Other Assets | 262 | 301 | 334 | 587 | 615 | 621 | 662 | 959 | 993 | 838 | 950 | 1,037 | 1,128 |
| Total Assets | 678 | 905 | 1,062 | 1,472 | 1,499 | 1,610 | 1,989 | 2,632 | 2,876 | 2,904 | 3,093 | 3,311 | 3,495 |
Below is a detailed analysis of the balance sheet data for Shilpa Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,427.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,362.00 Cr. (Mar 2025) to 2,427.00 Cr., marking an increase of 65.00 Cr..
- For Borrowings, as of Sep 2025, the value is 593.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 588.00 Cr. (Mar 2025) to 593.00 Cr., marking an increase of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 465.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 351.00 Cr. (Mar 2025) to 465.00 Cr., marking an increase of 114.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,495.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,311.00 Cr. (Mar 2025) to 3,495.00 Cr., marking an increase of 184.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,801.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,418.00 Cr. (Mar 2025) to 1,801.00 Cr., marking an increase of 383.00 Cr..
- For CWIP, as of Sep 2025, the value is 534.00 Cr.. The value appears to be declining and may need further review. It has decreased from 822.00 Cr. (Mar 2025) to 534.00 Cr., marking a decrease of 288.00 Cr..
- For Investments, as of Sep 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,128.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,037.00 Cr. (Mar 2025) to 1,128.00 Cr., marking an increase of 91.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,495.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,311.00 Cr. (Mar 2025) to 3,495.00 Cr., marking an increase of 184.00 Cr..
Notably, the Reserves (2,427.00 Cr.) exceed the Borrowings (593.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -60.00 | -68.00 | -76.00 | -36.00 | -46.00 | -171.00 | -665.00 | -481.00 | -699.00 | -698.00 | -272.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 48 | 43 | 80 | 102 | 101 | 99 | 88 | 124 | 113 | 125 | 126 |
| Inventory Days | 143 | 147 | 161 | 187 | 194 | 266 | 298 | 427 | 338 | 280 | 309 | 309 |
| Days Payable | 108 | 85 | 101 | 110 | 106 | 115 | 122 | 91 | 139 | 125 | 156 | 85 |
| Cash Conversion Cycle | 79 | 111 | 104 | 157 | 189 | 253 | 275 | 425 | 323 | 268 | 278 | 350 |
| Working Capital Days | 30 | 33 | 27 | 79 | 98 | 98 | 68 | 72 | 77 | -13 | 48 | 81 |
| ROCE % | 20% | 18% | 16% | 14% | 10% | 9% | 12% | 8% | 6% | 1% | 5% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Bandhan Small Cap Fund | 2,285,882 | 0.43 | 78.06 | 2,225,882 | 2025-12-15 03:53:38 | 2.7% |
| ICICI Prudential ELSS Tax Saver Fund | 2,065,936 | 0.47 | 70.55 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,926,298 | 1.02 | 65.78 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 447,198 | 0.3 | 15.27 | 411,529 | 2025-12-15 03:53:38 | 8.67% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 426,964 | 1.71 | 14.58 | N/A | N/A | N/A |
| WhiteOak Capital Mid Cap Fund | 292,082 | 0.23 | 9.97 | N/A | N/A | N/A |
| Aditya Birla Sun Life Manufacturing Equity Fund | 219,227 | 0.68 | 7.49 | N/A | N/A | N/A |
| ICICI Prudential Exports and Services Fund | 196,585 | 0.47 | 6.71 | 150,000 | 2025-12-15 03:53:38 | 31.06% |
| Aditya Birla Sun Life Retirement Fund - The 30s Plan | 79,100 | 0.63 | 2.7 | N/A | N/A | N/A |
| ITI Pharma and Healthcare Fund | 49,568 | 0.73 | 1.69 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.04 | 3.67 | -3.74 | 7.26 | 18.13 |
| Diluted EPS (Rs.) | 0.04 | 3.67 | -3.74 | 7.26 | 18.13 |
| Cash EPS (Rs.) | 19.69 | 16.66 | 7.88 | 16.59 | 24.77 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 242.58 | 208.37 | 204.41 | 208.65 | 180.00 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 242.58 | 208.37 | 204.41 | 208.65 | 180.00 |
| Revenue From Operations / Share (Rs.) | 131.55 | 132.67 | 120.98 | 131.97 | 110.53 |
| PBDIT / Share (Rs.) | 34.79 | 29.11 | 13.79 | 25.13 | 25.98 |
| PBIT / Share (Rs.) | 23.23 | 16.68 | 2.79 | 15.93 | 19.36 |
| PBT / Share (Rs.) | 12.64 | 6.81 | -3.97 | 12.20 | 24.14 |
| Net Profit / Share (Rs.) | 8.14 | 4.23 | -3.12 | 7.40 | 18.15 |
| NP After MI And SOA / Share (Rs.) | 8.01 | 3.67 | -3.74 | 6.99 | 18.13 |
| PBDIT Margin (%) | 26.44 | 21.94 | 11.39 | 19.03 | 23.50 |
| PBIT Margin (%) | 17.66 | 12.57 | 2.30 | 12.07 | 17.51 |
| PBT Margin (%) | 9.60 | 5.13 | -3.28 | 9.24 | 21.83 |
| Net Profit Margin (%) | 6.18 | 3.18 | -2.58 | 5.60 | 16.41 |
| NP After MI And SOA Margin (%) | 6.08 | 2.76 | -3.09 | 5.29 | 16.39 |
| Return on Networth / Equity (%) | 3.30 | 1.76 | -1.82 | 3.32 | 9.99 |
| Return on Capital Employeed (%) | 8.61 | 6.03 | 1.14 | 6.10 | 7.75 |
| Return On Assets (%) | 2.36 | 1.03 | -1.11 | 2.10 | 5.60 |
| Long Term Debt / Equity (X) | 0.09 | 0.30 | 0.16 | 0.19 | 0.32 |
| Total Debt / Equity (X) | 0.24 | 0.51 | 0.44 | 0.37 | 0.48 |
| Asset Turnover Ratio (%) | 0.40 | 0.38 | 0.36 | 0.12 | 0.36 |
| Current Ratio (X) | 1.46 | 1.26 | 0.98 | 1.45 | 1.52 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.57 | 0.86 | 0.99 |
| Inventory Turnover Ratio (X) | 3.71 | 1.28 | 1.10 | 0.35 | 1.16 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 14.78 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 6.38 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 85.22 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 93.62 | 0.00 |
| Interest Coverage Ratio (X) | 4.50 | 2.75 | 2.04 | 5.30 | 9.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.43 | 1.33 | 0.53 | 2.35 | 4.98 |
| Enterprise Value (Cr.) | 7032.84 | 4901.02 | 2756.04 | 4084.09 | 3310.97 |
| EV / Net Operating Revenue (X) | 5.47 | 4.26 | 2.62 | 3.57 | 3.67 |
| EV / EBITDA (X) | 20.67 | 19.40 | 23.03 | 18.73 | 15.63 |
| MarketCap / Net Operating Revenue (X) | 5.04 | 3.48 | 1.90 | 3.01 | 3.02 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 85.21 | 0.00 |
| Price / BV (X) | 2.73 | 2.21 | 1.12 | 1.89 | 1.84 |
| Price / Net Operating Revenue (X) | 5.04 | 3.48 | 1.90 | 3.01 | 3.02 |
| EarningsYield | 0.01 | 0.01 | -0.01 | 0.01 | 0.05 |
After reviewing the key financial ratios for Shilpa Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 3.67 (Mar 24) to 0.04, marking a decrease of 3.63.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 3.67 (Mar 24) to 0.04, marking a decrease of 3.63.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.69. This value is within the healthy range. It has increased from 16.66 (Mar 24) to 19.69, marking an increase of 3.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.58. It has increased from 208.37 (Mar 24) to 242.58, marking an increase of 34.21.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.58. It has increased from 208.37 (Mar 24) to 242.58, marking an increase of 34.21.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 131.55. It has decreased from 132.67 (Mar 24) to 131.55, marking a decrease of 1.12.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 34.79. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 34.79, marking an increase of 5.68.
- For PBIT / Share (Rs.), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 23.23, marking an increase of 6.55.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.64. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 12.64, marking an increase of 5.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has increased from 4.23 (Mar 24) to 8.14, marking an increase of 3.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.01. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.01, marking an increase of 4.34.
- For PBDIT Margin (%), as of Mar 25, the value is 26.44. This value is within the healthy range. It has increased from 21.94 (Mar 24) to 26.44, marking an increase of 4.50.
- For PBIT Margin (%), as of Mar 25, the value is 17.66. This value is within the healthy range. It has increased from 12.57 (Mar 24) to 17.66, marking an increase of 5.09.
- For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 5.13 (Mar 24) to 9.60, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 6.18. This value is within the healthy range. It has increased from 3.18 (Mar 24) to 6.18, marking an increase of 3.00.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.08. This value is below the healthy minimum of 8. It has increased from 2.76 (Mar 24) to 6.08, marking an increase of 3.32.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 15. It has increased from 1.76 (Mar 24) to 3.30, marking an increase of 1.54.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has increased from 6.03 (Mar 24) to 8.61, marking an increase of 2.58.
- For Return On Assets (%), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 5. It has increased from 1.03 (Mar 24) to 2.36, marking an increase of 1.33.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.30 (Mar 24) to 0.09, marking a decrease of 0.21.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.24, marking a decrease of 0.27.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has increased from 0.38 (Mar 24) to 0.40, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.26 (Mar 24) to 1.46, marking an increase of 0.20.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.71. This value is below the healthy minimum of 4. It has increased from 1.28 (Mar 24) to 3.71, marking an increase of 2.43.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.50. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 4.50, marking an increase of 1.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.33 (Mar 24) to 2.43, marking an increase of 1.10.
- For Enterprise Value (Cr.), as of Mar 25, the value is 7,032.84. It has increased from 4,901.02 (Mar 24) to 7,032.84, marking an increase of 2,131.82.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.47. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 5.47, marking an increase of 1.21.
- For EV / EBITDA (X), as of Mar 25, the value is 20.67. This value exceeds the healthy maximum of 15. It has increased from 19.40 (Mar 24) to 20.67, marking an increase of 1.27.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.73, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Shilpa Medicare Ltd:
- Net Profit Margin: 6.18%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.3% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.6 (Industry average Stock P/E: 53.56)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.18%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 12-6-214/A-1, Shilpa House, Raichur Karnataka 584135 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Omprakash Inani | Chairman |
| Mr. Vishnukant C Bhutada | Managing Director |
| Mr. Kalakota Sharath Reddy | Whole Time Director |
| Mr. Hetal Madhukant Gandhi | Independent Director |
| Mr. Arvind Vasudeva | Independent Director |
| Dr. Kamal K Sharma | Independent Director |
| Dr. Anita Bandyopadhyay | Independent Woman Director |
FAQ
What is the intrinsic value of Shilpa Medicare Ltd?
Shilpa Medicare Ltd's intrinsic value (as of 09 January 2026) is ₹162.77 which is 46.81% lower the current market price of ₹306.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹5,979 Cr. market cap, FY2025-2026 high/low of ₹502/265, reserves of ₹2,427 Cr, and liabilities of ₹3,495 Cr.
What is the Market Cap of Shilpa Medicare Ltd?
The Market Cap of Shilpa Medicare Ltd is 5,979 Cr..
What is the current Stock Price of Shilpa Medicare Ltd as on 09 January 2026?
The current stock price of Shilpa Medicare Ltd as on 09 January 2026 is ₹306.
What is the High / Low of Shilpa Medicare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Shilpa Medicare Ltd stocks is ₹502/265.
What is the Stock P/E of Shilpa Medicare Ltd?
The Stock P/E of Shilpa Medicare Ltd is 38.6.
What is the Book Value of Shilpa Medicare Ltd?
The Book Value of Shilpa Medicare Ltd is 125.
What is the Dividend Yield of Shilpa Medicare Ltd?
The Dividend Yield of Shilpa Medicare Ltd is 0.16 %.
What is the ROCE of Shilpa Medicare Ltd?
The ROCE of Shilpa Medicare Ltd is 7.82 %.
What is the ROE of Shilpa Medicare Ltd?
The ROE of Shilpa Medicare Ltd is 4.21 %.
What is the Face Value of Shilpa Medicare Ltd?
The Face Value of Shilpa Medicare Ltd is 1.00.